PolyArginine Treated vEiN grafTs (PATENT)

Summary

The primary objectives of this trial are: 1) to evaluate the safety of NONA-L-ARGININE in ex vivo application to saphenous vein segments prior to grafting; and, 2) to obtain preliminary data on the biological effects of NONA-L-ARGININE, as compared to placebo, in the prevention of neointimal hyperplasia.

Timeline

Start

2005-03

Primary completion

2008-04

Completion

2008-04

Outcome

Outcome not reported

Stopped: “Reformulation of test compound”

Drugs

Indications